The Onco-Hu® platform is a robust immuno-oncology platform for efficacy testing of novel immunotherapies targeting T cells, NK cells, dendritic cells and myeloid cells. This platform is based on study-ready CD34 or PBMC humanized NSG and NSG transgenic variants engrafted with the tumor of your choice.
Bridge the gap between animal studies and translatable human response by choosing Onco-Hu models:
Onco-Hu models develop and express a broad range of functional immune cells, including:
Example Onco-Hu® Study Design with JAX Humanized Mice
In vivo readouts, 3 times weekly:
Endpoint:
Ex vivo:
We offer customizable study designs, to test the effectiveness of novel or existing therapeutic compounds such as T Cell Engagers or In Vivo CAR Generation to advance cancer research and enable the selection of immunotherapies and personalized cancer treatments. Typically, cohorts of PDX or CDX bearing CD34+ NSG™ mice are randomized onto a study when tumors reach ~100 mm3. A standard study design is customizable to your specifications in collaboration with your dedicated In Vivo Pharmacology Study Director and their team.
JAX's humanized platform for the evaluation of immunotherapeutic safety assesses therapeutics in the context of the human immune system as they engage human tumors or other tissues. The CRS platform provides a scalable, reproducible, and translationally relevant examination of immunotherapies as compared to other models such as in vitro assays or non-human primates which do not account for complex human biology or lack human relevant immune substrates for engagement.
Work with our experts to select the right mouse strains, donors, tumor models, measures, and endpoints to get a complete picture of your therapeutic's safety profile. Choose your preferred tumor cell line(s), or test against reference compounds in the absence of tumors. Then let us guide you in selecting PBMC donors, mouse models, and a battery of informative assays.
Immune humanized mice enable in vivo preclinical analysis of human specific immuno-modulatory therapeutics. CD34+ HSC engrafted NSG-SGM3-IL15 mice were co-engrafted with the MDA-MB-453 breast cancer cell line with low EGFR tumor target expression. Mice were treated with an EGFRxCD3 bispecific or Avelumab (anti-PD-L1 mAb) alone or in combination. Combinatorial treatment enhanced control over tumor growth compared to monotherapy and demonstrated enhanced infiltration of human CD4+ and CD8+ T cells (and not CD56+ NK cells), confirming drug mediated mechanism of action.
Study-ready Onco-Hu cohorts can be shipped to your laboratory for independent immunotherapeutic safety, efficacy and toxicity assessments. CD34+ NSG or transgenic variant mice dually engrafted with a PDX of choice are a robust pre-clinical tool for assessing proof-of-concept treatment strategies and modeling of pathways important in therapeutic intervention. Remove the tumor engraftment optimization of your workflow and focus on evaluating your therapeutic or biological question.
Chat with our experts to help you choose the right mouse strain, cell donors, tumor models and cohort sizes for your experiments.
JAX practical guide to selecting the optimal combination of immune-humanized mouse models and tumor xenografts. Don't miss this informative presentation for constructing your preclinical studies.
